Guerbet SA
GBT
Company Profile
Business description
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
Contact
15 rue des Vanesses
Zone Paris Nord II
Villepinte93420
FRAT: +33 145915000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
1,034
Stocks News & Analysis
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
stocks
Major ASX listed miners overvalued
We’ve adjusted our fair values after updating our commodity price assumptions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.60 | 19.70 | -0.22% |
| CAC 40 | 8,054.84 | 57.18 | -0.70% |
| DAX 40 | 24,708.78 | 250.28 | -1.00% |
| Dow JONES (US) | 48,898.58 | 460.75 | -0.93% |
| FTSE 100 | 10,114.02 | 81.33 | -0.80% |
| HKSE | 26,487.51 | 76.39 | -0.29% |
| NASDAQ | 23,202.33 | 313.06 | -1.33% |
| Nikkei 225 | 52,991.10 | 592.47 | -1.11% |
| NZX 50 Index | 13,573.93 | 6.36 | -0.05% |
| S&P 500 | 6,867.56 | 72.45 | -1.04% |
| S&P/ASX 200 | 8,815.90 | 20.70 | -0.23% |
| SSE Composite Index | 4,113.65 | 0.35 | -0.01% |